Loading...
XASX
GSS
Market cap39mUSD
Dec 05, Last price  
0.27AUD
1D
-3.64%
1Q
-5.36%
Jan 2017
-41.11%
IPO
-39.77%
Name

Genetic Signatures Ltd

Chart & Performance

D1W1MN
XASX:GSS chart
P/E
P/S
3.79
EPS
Div Yield, %
Shrs. gr., 5y
11.77%
Rev. gr., 5y
7.14%
Revenues
16m
+62.81%
256,9771,292,5291,043,2693,265,7874,061,5464,993,7557,024,00011,263,00028,284,00035,421,00016,939,0009,766,00015,900,000
Net income
-20m
L+12.55%
-2,014,401-1,728,487-2,659,120-3,026,598-2,670,622-3,253,809-3,492,000-2,085,9991,756,0003,063,000-14,052,000-17,862,000-20,104,000
CFO
-12m
L+21.43%
-1,186,909-1,354,737-2,795,142-2,572,311-2,571,868-3,693,561-2,269,000-9,494,0004,195,0009,806,000-12,451,000-10,120,000-12,289,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
IPO date
Mar 31, 2015
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT